Quest PharmaTech Inc.  

(Public, CVE:QPT)   Watch this stock  
Find more results for CVE:qpt
0.0400
+0.0050 (14.29%)
Sep 19 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.04 - 0.04
52 week 0.03 - 0.10
Open 0.04
Vol / Avg. 48,500.00/22,046.00
Mkt cap 4.07M
P/E     -
Div/yield     -
EPS 0.00
Shares 101.70M
Beta 0.16
Inst. own     -

Key stats and ratios

Q2 (Apr '14) 2014
Net profit margin -238.36% -14.12%
Operating margin -227.59% -8.54%
EBITD margin - -6.31%
Return on average assets -278.12% -47.57%
Return on average equity - -
CDP Score - -

Address

8123 Roper Road NW
EDMONTON, AB T6E 6S4
Canada
+1-780-4481400 (Phone)
+1-780-4160324 (Fax)

Website links

Description

Quest PharmaTech Inc. (Quest) is a biotechnology company. The Company is engaged in the discovery, development and commercialization of pharmaceutical products. It is developing a portfolio of product candidates for the treatment of cancer by combining immunotherapeutic antibodies with chemotherapy, photodynamic therapy, radio immunotherapy or immunoadjuvants. Quest is also developing a series of products for the treatment of cancer and dermatological conditions, based on the Company´┐Żs SonoLight Technology platform. Quest is developing high affinity monoclonal antibodies targeting certain tumour associated antigens that are presented in various cancers, including ovary, pancreas, lung, breast, prostate and stomach. Quest is developing the affinity monoclonal antibody Oregovomab (MAb B43.13) for the treatment of ovarian cancer.

Officers and directors

Lorne Meikle Independent Chairman of the Board
Ragupathy Madiyalakan Ph.D. Chief Executive Officer, Director
Pierre Vermette Chief Financial Officer
Thomas Woo Vice President - Product Development
Ian McConnan Independent Director
Paul J. Van Damme Independent Director